Crossject S.A.
PAR: ALCJ.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Patrick Alexandre
- Employees
- 112
- Headquarters
- Dijon, France
- IPO year
- 2014
- Market cap
- €101.2M
- Website
- https://www.crossject.com
Loading ALCJ…
Loading profile data…Frequently asked questions about ALCJ
What does Crossject S.A. (ALCJ.PA) do?
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment...
Where does ALCJ.PA trade?
Crossject S.A. (ALCJ.PA) trades on the Euronext Paris.
What sector is ALCJ.PA in?
Crossject S.A. (ALCJ.PA) operates in the Healthcare sector, specifically in the Medical - Instruments & Supplies industry.
Who is the CEO of Crossject S.A.?
Patrick Alexandre is the chief executive officer of Crossject S.A. (ALCJ.PA).
Where is Crossject S.A. headquartered?
Crossject S.A. is headquartered in France.
Does ALCJ.PA pay a dividend?
Crossject S.A. (ALCJ.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALCJ.PA go public?
Crossject S.A. (ALCJ.PA) completed its initial public offering in 2014.